Mark Leahey's guest appearances

Mark Leahey

Pharma Intelligence Podcasts

DeviceTalks

The Other Side with Joe Mullings

Market Pathways

Scott Whitaker

Nadim Yared

Mark McClellan

Johns Hopkins

Jeff Allen

John Brown

David Spangler

Joe Jimenez

Richard Thompson

Dean Kamen

Paul Walker

Mike Mahoney

Peter Marks

Janet Woodcock

Tim Davis

OwlTail

As the calendar turns from summer to fall, there is no shortage of issues important to the medical device industry emerging on all fronts, addressing legislative, regulatory and policy matters. No one is better aware of the state of play of these issues than Mark Leahey, CEO of MDMA. Here Mark touches all bases with Medtech Strategist/Market Pathways editor-in-chief Stephen Levin, including discussing:  the potential long-term impact of the pandemic on the industry and the transition from EUAs to permanent approvals/clearances; an inside look at the current status of the MDUFA/user fee negotiations, including whether we could see an FDA “concierge” program; what we might expect from the CURES 2.0 legislation—is ARPA-Health in our future?; reimbursement challenges, including parallel review, coverage of advanced technologies such as AI, and the debate on site of service payment rules; is prior authorization dead?; and will the drug pricing debate spill over into medical devices?

As the calendar turns from summer to fall, there is no shortage of issues important to the medical device industry emerging on all fronts, addressing legislative, regulatory and policy matters. No one is better aware of the state of play of these issues than Mark Leahey, CEO of MDMA. Here Mark touches all bases with Medtech Strategist/Market Pathways editor-in-chief Stephen Levin, including discussing: <ul> <li>the potential long-term impact of the pandemic on the industry and the transition from EUAs to permanent approvals/clearances;</li> <li>an inside look at the current status of the MDUFA/user fee negotiations, including whether we could see an FDA “concierge” program;</li> <li>what we might expect from the CURES 2.0 legislation—is ARPA-Health in our future?;</li> <li>reimbursement challenges, including parallel review, coverage of advanced technologies such as AI, and the debate on site of service payment rules;</li> <li>is prior authorization dead?; and</li> <li>will the drug pricing debate spill over into medical devices?</li></ul>

A Look Ahead at the Coming Medtech “School Year”: A Conversation with MDMA’s Mark Leahey

Art Collins

Spencer Stiles

DeviceTalks Weekly listeners will need some gravy to digest this Thanksgiving feast-sized podcast featuring news and insights from three stellar guests in addition to two new installments of #2minutedetalks chapters from Delve Inc. and Explorer Surgical.This week we visit with…Mark Leahey, president of the Medical Device Manufacturers Association, who explains where medtech might fits in this evolving political climate.Spencer Stiles, group president of orthopaedic and spine at Stryker, who shares details on the Wright acquisition and the secret to the success of placing MAKO surgical robots in hospitalsArt Collins, senior advisor to Explorer Surgical. The former Chairman and CEO discusses leadership, Medtronic and the future for startups like Explorer.Also co-host Chris Newmarker, executive editor of MassDevice, shares his selections for this week’s #newmarkersnewsmakers which includes news from BD, Boston Scientific and Johnson &amp; Johnson.

DeviceTalks Weekly listeners will need some gravy to digest this Thanksgiving feast-sized podcast featuring news and insights from three stellar guests in addition to two new installments of #2minutedetalks chapters from Delve Inc. and Explorer Surgical. This week we visit with… Mark Leahey, president of the Medical Device Manufacturers Association, who explains where medtech might fits in this evolving political climate. Spencer Stiles, group president of orthopaedic and spine at Stryker, who shares details on the Wright acquisition and the secret to the success of placing MAKO surgical robots in hospitals Art Collins, senior advisor to Explorer Surgical. The former Chairman and CEO discusses leadership, Medtronic and the future for startups like Explorer. Also co-host Chris Newmarker, executive editor of MassDevice, shares his selections for this week’s #newmarkersnewsmakers which includes news from BD, Boston Scientific and Johnson &amp; Johnson.

Enjoy a feast of insights from Spencer Stiles(Stryker) Art Collins(Explorer) and Mark Leahey (MDMA)

In a phone interview with Medtech Insight, MDMA CEO Mark Leahey talked about the industry group's ongoing efforts to fully repeal the medical device tax, 2018 priorities, the emerging digital health sector and more.

MDMA’s Mark Leahey Talks Device Tax, Year Ahead